Sun Pharma receives DCGI approval for generic version of semaglutide injection
Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity.
Layer-by-Layer Polymeric Films: A Novel Approach to Buccal GLP-1 Delivery
Buccal delivery offers a promising alternative to oral drug administration by enabling direct systemic absorption and avoiding first-pass metabolism. Multilayer polymeric films represent a promising strategy for the sequential delivery of drug and absorption enhancer in the oral cavity. Here, dual- and triple-layer films were fabricated via slot-die coating, incorporating a GLP-1 receptor agonist (GLP-1-RA) […]
Ozempic Made Weight Loss Therapy Mainstream, But Now It’s Getting Competition
Who would have ever thought that a weight loss injectable would become a household name and pop culture-adjacent phenomenon? Ozempic has become synonymous with modern weight-loss, discussed just as casually as the latest iPhone or sneaker drop. But the era of semaglutide’s unquestioned dominance seems to be slipping with more and more weight loss drugs […]
How will weight-loss jabs change the food industry?
Richard M Lee/Shutterstock Consumers are surrounded by food that is highly conducive to weight gain. No one likes dieting and very few have lasting success. But now weight-loss injections are seen as gamechangers, yielding results that seem miraculous for people who have struggled with their weight. Around the world, obesity, high blood pressure, and abnormal […]
Study sheds light on weight regain after GLP-1 discontinuation
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests – Reuters
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests Reuters
Why Environment Matters More When Using GLP-1 Medications
GLP-1 medications can create opportunity for change—but environment determines what lasts. Discover how context shapes habits more than motivation alone.
Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
What happens after GLP-1s and why food will matter more than ever
A University of Oxford study published in The BMJ finds users of GLP-1 drugs like Ozempic regain weight and reverse heart health improvements within two years of stopping treatment.
China-founded pharma Corxel raises up to $287M for oral GLP-1
Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as …